Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma

BACKGROUND: Sorafenib was the first Food and Drug Administration approved anti-angiogenic therapy for renal cell carcinoma (RCC). Currently, there are no validated predictive biomarkers for sorafenib. Our purpose was to determine if sorafenib target expression is predictive of sorafenib sensitivity....

Descripción completa

Detalles Bibliográficos
Autores principales: Aziz, Saadia A, Sznol, Joshua A, Albiges, Laurence, Zito, Christopher, Jilaveanu, Lucia B, Camp, Robert L, Escudier, Bernard, Kluger, Harriet M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896780/
https://www.ncbi.nlm.nih.gov/pubmed/24423208
http://dx.doi.org/10.1186/1475-2867-14-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896780/
https://www.ncbi.nlm.nih.gov/pubmed/24423208
http://dx.doi.org/10.1186/1475-2867-14-4

Ejemplares similares